Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary

Hiroaki Kajiyama, Satoyo Hosono, Mikio Terauchi, Kiyosumi Shibata, Kazuhiko Ino, Eiko Yamamoto, Seiji Nomura, Akihiro Nawa, Fumitaka Kikkawa

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Objectives: Twist is a highly conserved basic helix-loop-helix transcription factor that regulates the expression of E-cadherin and promotes the epithelial-mesenchymal transition, which is critical for tumor infiltration. We examined the distribution and expression of this molecule in clear cell carcinoma of the ovary (CCC) to elucidate their clinical significance. Methods: Paraffin sections from CCC tissues (n = 27) were immunostained with Twist antibody and staining intensities were evaluated. Stratified with various clinicopathological factors, overall survival (OS) and progression-free survival (PFS) were evaluated. Results: In the 27 carcinomas, negative Twist immunoexpression was observed in 14 cases (51.9%), and positive immunoexpression in 13 (48.1%). Twist, when categorized into negative versus positive expression, was associated with FIGO stage and peritoneal cytology. In addition, positive Twist expression significantly predicted a poorer OS and PFS compared with negative expression (p < 0.0001). Furthermore, the multivariate analyses revealed that positive Twist expression was an independent prognostic factor for OS and PFS of patients with CCC in this study (p = 0.0077 and 0.0033, respectively). Conclusion: The current findings suggest that the assessment of Twist immunoreactivity may be a useful prognostic indicator and that Twist may play a critical role in the progression of CCC.

Original languageEnglish
Pages (from-to)394-401
Number of pages8
Issue number5-6
Publication statusPublished - 10-2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary'. Together they form a unique fingerprint.

Cite this